A diagnostic protein assay for differentiating follicular thyroid adenoma and carcinoma
Sun, Y.; Wang, H.; Li, L.; Wang, J.; Chen, W.; Peng, L.; Hu, P.; Yu, J.; Cai, X.; Yao, N.; Zhou, Y.; Wang, J.; Wang, Y.; Qian, L.; Ge, W.; Chen, M.; Yang, F.; Gui, Z.; Sun, W.; Wang, Z.; Ge, M.; He, Y.; Wang, G.; Zhao, Y.; Chen, H.; Wu, X.; Du, Y.; Wei, W.; Wu, F.; Luo, D.; Lin, X.; Zheng, H.; Zhu, X.; Wei, B.; Shen, J.; Yao, J.; Yuan, Z.; Liu, T.; Pan, J.; Zhang, Y.; Lv, Y.; Guo, Q.; Wu, Q.; Gong, T.; Chen, T.; Zheng, S.; Zhu, J.; Liu, H.; Chen, C.; Han, H.; Selvarajan, S.; Xing, M.; Kakudo, K.; Alexander, E. K.; Wu, Y.; Wang, Y.; Xu, D.; Zhang, H.; Nie, X.; Kon, O. L.; Iyer, N. G.; Liu, Z.;
Show abstract
Differentiating follicular thyroid adenoma (FTA) from carcinoma (FTC) remains challenging due to similar histological features separate from invasion. In this study, we aim to develop and validate DNA and protein-based classifiers for FTA/FTC differentiation. We collected 2443 samples from 1568 patients across 24 centers and applied next-generation sequencing, as well as discovery and targeted proteomics. Machine learning models were developed and compared utilizing DNA and/or protein features. The discovery protein-based model (AUC 0.899) outperformed the gene-based model (AUC 0.670). Consequently, we generated a protein-based model with targeted mass spectrometry and further validated it in three independent testing sets. The 24-protein-based model achieved high performance in the retrospective sets (AUC 0.871 and 0.853) and the prospective fine-needle aspiration biopsies (AUC 0.781). The classifier notably illustrated a 95.7% negative predictive value for ruling out malignant nodules. This study offers a promising protein-based approach for differential diagnosis of FTA and FTC. HighlightsO_LIGenetic and proteomic profiling of follicular thyroid tumors from 1568 patients across 24 centers C_LIO_LIAI model based on proteins (AUC 0.899) outperformed that based on gene mutations (AUC 0.670) for differentiation of FTA and FTC C_LIO_LIValidation of the protein model in two retrospective cohorts (AUCs: 0.871, 0.853) and a prospective (AUC 0.781) C_LIO_LIThe protein model has 95.7% negative predictive value for ruling out malignant nodules C_LI
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Deep plasma proteomics identifies and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer 93%
- Machine learning-based proteogenomic data modeling identifies circulating plasma biomarkers for early detection of lung cancer 92%
- Deep Proteome Profiling of Metabolic Dysfunction-Associated Steatotic Liver Disease 91%
Similar papers in this journal
- Proteomics study of colorectal cancer and adenomatous polyps identifies TFR1, SAHH, and HV307 as potential biomarkers for screening 95%
- Identification of plasma proteins associated with oesophageal cancer chemotherapeutic treatment outcomes using SWATH-MS 94%
- SHIP1 modulation and proteome characterization of microglia 93%
Similar papers in this journal
- A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes 94%
- A Large-Scale Proteomics Resource of Circulating Extracellular Vesicles for Biomarker Discovery in Pancreatic Cancer 92%
- Cerebrospinal fluid proteome maps detect pathogen-specific host response patterns in meningitis. 92%
Similar papers in this journal
- Proteogenomic Characterization of Triple-Negative Apocrine Carcinoma Reveals Molecular Features of Progression and Chemotherapy Response 95%
- A Proteomic Platform to Identify Off-Target Proteins Associated with Therapeutic Modalities that Induce Protein Degradation or Gene Silencing 93%
- Survival analysis in breast cancer using proteomic data from four independent datasets 93%